Physician profile
Wei Wang
NPI 1497330849
$8,967.66
in general payments reported to CMS, 2019-2025
70 companies · $2,744 in 2025
The $2,744 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $1,087 · 2023: $1,599 · 2024: $3,240 · 2025: $2,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,984 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,983.54 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $319.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,679.31 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $838.83 | 2022-2025 | Lynparza, Datroway, Tagrisso |
| Merck Sharp & Dohme LLC | $703.51 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $507.71 | 2024-2025 | |
| Genentech USA, INC. | $327.86 | 2022-2025 | Tecentriq, Alecensa, Gavreto |
| Janssen Biotech, INC. | $289.25 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $273.84 | 2022-2025 | |
| Incyte Corporation | $265.43 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Celgene Corporation | $230.10 | 2022-2025 | Reblozyl, Pomalyst, Pomalyst |
| Gilead Sciences, INC. | $218.37 | 2023-2025 | Trodelvy |
| Daiichi Sankyo INC. | $206.12 | 2023-2025 | Enhertu, Injectafer |
| Pharmacosmos Therapeutics INC. | $183.26 | 2022-2025 | Monoferric |
| Lilly USA, LLC | $158.81 | 2022-2025 | Jaypirca, Retevmo, Verzenio |
| Array Biopharma INC | $149.93 | 2023-2025 | Braftovi, Mektovi, Xalkori |
| Eisai INC. | $138.10 | 2022-2024 |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.